Subject: Biotech and Medical Sciences

Why in the News?

Novo Nordisk launched Awiqli (insulin icodec), the world’s first once-a-week insulin injection, in India, cutting required insulin shots from 365 to 52 a year at Rs 261 per week. The launch targets India’s exceptionally large and growing diabetic population, but insulin use in India has long lagged clinical need because of reluctance among both patients and doctors to initiate insulin therapy.

How does icodec technically reduce insulin’s dosing burden without changing its clinical effect?

1. Albumin-binding depot: A fatty acid chain added to the insulin molecule increases its affinity for albumin, a blood protein. Delivered under the skin, the drug binds reversibly to albumin, forming an inactive depot that releases insulin into the bloodstream through the week.
2. Reduced receptor affinity: Three amino acid substitutions lower the molecule’s affinity for insulin receptors. This slows the rate at which released insulin is used up, without reducing its potency.
3. Injection frequency reduction: The two modifications together cut insulin injections from 365 days a year to 52 days, making icodec the world’s first long-acting weekly insulin shot.
4. Clinical equivalence, not clinical superiority: Physicians state icodec’s blood sugar-lowering effect is similar to other insulins. The advance lies in reduced dosing frequency, expected to improve compliance rather than glucose control itself.
5. Position in insulin’s evolution: Icodec is a genetically engineered insulin analogue (Insulin analogue: a modified version of human insulin engineered to alter how long it stays active or how it is absorbed), part of a line of modifications that extend how long insulin stays active in the body.

Why does India’s insulin gap persist despite insulin’s proven superiority over oral therapy?

1. Patient reluctance despite clinical failure of pills: Type 2 diabetics who have failed to control blood glucose even on the highest doses of oral medicines remain unwilling to switch to insulin shots, despite the risk of organ, nerve, and eye damage from delay.
2. Physician-side reluctance: Doctors themselves show reluctance to initiate insulin treatment in patients, delaying transition even when maximal oral therapy has failed.
3. Insulin’s undeserved stigma: Novo Nordisk India’s managing director states insulin is a drug that is never abused and is highly effective, yet patients avoid it, indicating the barrier is perceptual rather than clinical.
4. Scale of underuse: Only six million people are currently on insulin in India, a number industry estimates should be at least double, given the population that clinically needs it.
5. Gendered burden compounding avoidance: Women on multiple daily insulin doses report needing to adjust doses during menstruation, a flexibility burden not addressed by frequency reduction alone.

Which patient groups does icodec target, and why does the clinical logic differ between type 1 and type 2 diabetes?

1. First target group: treatment-failed type 2 diabetics: Patients with eight to ten years of diabetes whose pills can no longer control blood glucose are the primary intended users, to prevent further organ and nerve damage from delay.
2. Second target group: background insulin for type 1 diabetics: Type 1 diabetics need a long-acting basal dose (Basal dose: a steady, long-acting insulin dose that manages blood glucose between meals) alongside meal-time bolus doses (Bolus dose: a fast-acting insulin dose taken around mealtimes based on calorie intake); icodec would add a fourth weekly dose without significantly raising treatment burden.
3. Why type 2 is the better clinical fit: Type 1 diabetics already take three daily doses, and their blood glucose fluctuates more, requiring frequent dose adjustment that weekly dosing cannot accommodate.
4. Loss of flexibility as a trade-off: A physician-run survey found women needed to adjust insulin doses during menstruation, a flexibility that a fixed weekly dose foreclosed for type 1 patients.
5. Type 2’s larger untapped pool: Since 25% to 30% of type 2 diabetics eventually require insulin despite most managing initially on pills, this is the segment with the largest late-stage conversion potential.

Does icodec’s safety and cost profile remove the practical objections to insulin therapy?

1. Hypoglycemia risk unchanged: The most common side effect, hypoglycemia (Hypoglycemia: a condition where blood glucose levels fall too low), affects about one in ten people on icodec, matching the risk seen with other daily insulin shots.
2. Why hypoglycemia appears more noticeable on insulin: Blood glucose is controlled for the first time once insulin is started, making hypoglycemic episodes more apparent; pills can cause hypoglycaemia too, but uncontrolled high glucose on pills masks the comparison.
3. Weekly cost undercuts existing insulin analogues: Icodec costs Rs 261 a week, compared to Rs 345 to Rs 453 a week for existing insulin analogues, working out to about Rs 50 a day.
4. Pricing structure: The drug is sold in two pre-filled pen sizes, a 700 ml unit priced at Rs 2,611 and a 2,100 ml unit priced at Rs 7,883, with a typical patient needing around 70 units a week depending on requirement.
5. Combination potential with weight-loss drugs: Icodec becomes more effective when combined with GLP-1 drugs (GLP-1 drugs: a class of medicines that lower blood glucose and are also used for weight loss), since abdominal obesity reduces insulin sensitivity and raises the insulin needed to process the same amount of sugar.

Does convenience alone close India’s insulin treatment gap?

1. Scale of the underlying burden: India currently has 101 million people living with diabetes and 136 million with pre-diabetes, one of the largest such populations in the world.
2. Projected insulin need over time: Industry estimates suggest 5% to 10% of diabetics would need insulin after five years of pill-based management, rising to 20% to 30% after ten years.
3. Conservative estimate still implies a large gap: Even at a conservative 20% requirement, the number needing insulin would stand at around 20 million, more than three times the current six million on insulin.
4. Convenience as the stated lever for closing this gap: Industry framing ties the drug’s adoption prospects explicitly to convenience and comparable cost, not to any claimed improvement in glucose control.
5. Unaddressed question: Whether reduced dosing frequency by itself overcomes the reluctance documented among both patients and doctors, distinct from cost or frequency, is not established by the launch itself.

Conclusion

Icodec’s weekly dosing and competitive pricing directly target the practical barriers of frequency and cost that have long deterred insulin use in India. The deeper barrier is behavioural: both patients and physicians delay insulin initiation despite its established superiority over maximal oral therapy, driven by stigma and reluctance rather than price or frequency alone. Reducing shots from 365 to 52 a year does not by itself address this psychological resistance. Whether convenience translates into earlier insulin initiation, and closes the gap between India’s 101 million diabetics and the roughly 20 million projected to eventually need insulin, will depend on physician-driven behavioural change as much as on the drug’s technical advance.